Search Within

Renier J Brentjens

Formats
  1. Meeting Abstract (149)
  2. Journal Article (125)
  3. Review (5)
  4. Editorial (3)
  5. Book Section (1)
  6. Conference Paper (1)
  7. Guidelines (1)
  8. Research Letter (1)
Groups
  1. Adult Leukemia (286)
  2. Center for Hematologic Malignancies (286)
  3. Department of Medicine (286)
  4. GSK Faculty (286)
  5. Hematologic Malignancies Research (286)
  6. Hematologic Malignancies, Division of (286)

More Groups

People
  1. Michel Sadelain (116)
  2. Isabelle Riviere (111)
  3. Jae Park (105)
  4. Xiuyan Wang (66)
  5. Terence Purdon (60)
  6. Elizabeth Halton (48)

More People

Years
  1. 2025 (2)
  2. 2023 (3)
  3. 2022 (5)
  4. 2021 (17)
  5. 2020 (26)
  6. 2019 (28)

More Years

Publications
  1. Blood (74)
  2. Journal of Clinical Oncology (26)
  3. Molecular Therapy (21)
  4. Cancer Research (10)
  5. Biology of Blood and Marrow Transplantation (8)
  6. Clinical Cancer Research (8)

More Publications

Publishers
  1. American Society of Hematology (79)
  2. Nature Publishing Group (52)
  3. American Association for Cancer Research (29)
  4. American Society of Clinical Oncology (27)
  5. Elsevier Inc. (25)
  6. Cell Press (6)

More Publishers

Results (286)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Loss of the HVEM tumor suppressor in lymphoma and restoration by modified CAR-T cells
    Journal Article

    Boice, M.; Salloum, D.; Mourcin, F.; Sanghvi, V.; Amin, R.; Oricchio, E.; Jiang, M.; Mottok, A.; Denis-Lagache, N.; Ciriello, G.; more...
    Cell (2016)

    Fulltext@MSK | Save
  • Impact of disease burden on long-term outcome of CD19-targeted CAR modified T cells in adult patients with relapsed B-ALL
    Meeting Abstract

    Park, J.; Riviere, I.; Wang, X.; Sadelain, M.; Brentjens, R.
    Haematologica (2016)

    Fulltext@MSK | Save
  • CD19-targeted CAR T-cell therapeutics for hematologic malignancies: Interpreting clinical outcomes to date
    Journal Article

    Park, J. H.; Geyer, M. B.; Brentjens, R. J.
    Blood (2016)

    Fulltext@MSK | Save
  • Driving CAR T-cells forward
    Journal Article

    Jackson, H. J.; Rafiq, S.; Brentjens, R. J.
    Nature Reviews Clinical Oncology (2016)

    Fulltext@MSK | Save
  • The future of cancer treatment: Immunomodulation, CARs and combination immunotherapy
    Journal Article

    Khalil, D. N.; Smith, E. L.; Brentjens, R. J.; Wolchok, J. D.
    Nature Reviews Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Medical management of side effects related to CAR T cell therapy in hematologic malignancies
    Journal Article

    Namuduri, M.; Brentjens, R. J.
    Expert Review of Hematology (2016)

    Fulltext@MSK | Save
  • Engineering armored T cell receptor-mimic (TCRm) chimeric antigen receptor (CAR) T cells specific for the intracellular protein Wilms tumor 1 (WT1) for treatment of hematologic and solid malignancies
    Meeting Abstract

    Rafiq, S.; Purdon, T.; Dao, T.; Liu, C.; Scheinberg, D.; Brentjens, R. J.
    Molecular Therapy (2016)

    Fulltext@MSK | Save
  • Chimeric antigen receptor T cells for cancer immunotherapy
    Meeting Abstract

    Curran, K. J.; Silverman, L. B.; Kobos, R.; Kernan, N. A.; Margossian, S. P.; Park, J. H.; Sauter, C. S.; Szenes, V.; Wang, X. Y.; O'Reilly, R. J.; more...
    Cancer Research (2016)

    Fulltext@MSK | Save
  • Toxicity and management in CAR T-cell therapy
    Journal Article

    Bonifant, C. L.; Jackson, H. J.; Brentjens, R. J.; Curran, K. J.
    Molecular Therapy - Oncolytics (2016)

    Fulltext@MSK | Save
  • Moving CAR T cell therapy forward: CARs and armored CARs
    Meeting Abstract

    Brentjens, R. J.
    Clinical Cancer Research (2016)

    Fulltext@MSK | Save